LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: A randomized controlled trial

Journal of Gynecologic Oncology

Volumn 24, Issue 2, 2013, Pages 128-134

  Abu Hashim, Hatem ^a   Zayed, Abdelhady ^a   Ghayaty, Essam ^a   El Rakhawy, Mohamed ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Abnormal uterine bleeding; Endometrial hyperplasia; Levonorgestrel releasing intrauterine system; Non atypical; Norethisterone acetate

Indexed keywords

CIDOLUT NOR; LEVONORGESTREL; NORETHISTERONE ACETATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLIMACTERIUM; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MAJOR CLINICAL STUDY; NON ATYPICAL ENDOMETRIAL HYPERPLASIA; OUTCOME ASSESSMENT; OUTPATIENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK FACTOR; TREATMENT DURATION;

EID: 84881379307     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2013.24.2.128     Document Type: Article

References (36)

1. Gultekin M, Dogan NU, Aksan G, Ozgul N. Management of endometrial hyperplasia. Minerva Ginecol 2010;62:433-445.
2. Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009;200:678.e1-e6.
3. Anastasiadis PG, Skaphida PG, Koutlaki NG, Galazios GC, Tsikouras PN, Liberis VA. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. Eur J Gynaecol Oncol 2000;21:131-134.
4. Espindola D, Kennedy KA, Fischer EG. Management of abnormal uterine bleeding and the pathology of endometrial hyperplasia. Obstet Gynecol Clin North Am 2007;34:717-737.
5. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of untreated hyperplasia in 170 patients. Cancer 1985;56:403-412.
6. Lacey JVJr, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 2009;63:39-44.
7. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:812-819.
8. Eddib A, Allaf B, Lee J, Yeh J. Risk for advanced-stage endometrial cancer in surgical specimens from patients with complex endometrial hyperplasia with atypia. Gynecol Obstet Invest 2012;73:38-42.
9. Marsden DE, Hacker NF. Optimal management of endo-metrial hyperplasia. Best Pract Res Clin Obstet Gynaecol 2001;15:393-405.
10. Koskas M, Azria E, Walker F, Luton D, Madelenat P, Yazbeck C. Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility. Anticancer Res 2012;32:1037-1043.
11. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012;125:477-482.
12. Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, et al. Management of endometrial precancers. Obstet Gynecol 2012;120:1160-1175.
13. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv 2004;59:368-378.
14. Reed SD, Voigt LF, Newton KM, Garcia RH, Allison HK, Epplein M, et al. Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet Gynecol 2009;113:655-662.
15. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989;160:126-131.
16. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:547.e1-e10.
17. Haoula ZJ, Walker KF, Powell MC. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 2011;159:176-179.
18. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 1982;17:529-536.
19. Phillips V, Graham CT, Manek S, McCluggage WG. The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology. J Clin Pathol 2003;56:305-307.
20. Guttinger A, Critchley HO. Endometrial effects of intrauterine levonorgestrel. Contraception 2007;75(6):S93-S98.
21. Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 2004;14:348-353.
22. Bese T, Vural A, Ozturk M, Dagistanli F, Demirkiran F, Tuncdemir M, et al. The effect of long-term use of progesterone therapy on proliferation and apoptosis in simple endometrial hyperplasia without atypia. Int J Gynecol Cancer 2006;16:809-813.
23. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endo-metrial hyperplasia--a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169-175.
24. Lee SY, Kim MK, Park H, Yoon BS, Seong SJ, Kang JH, et al. The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. J Gynecol Oncol 2010;21:102-105.
25. Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111:68-73.
26. Haimovich S, Checa MA, Mancebo G, Fuste P, Carreras R. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device. Menopause 2008;15:1002-1004.
27. Orbo A, Arnes M, Pettersen I, Larsen K, Hanssen K, Moe B. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system. Acta Obstet Gynecol Scand 2010;89:1438-1446.
28. Jensen JT, Nelson AL, Costales AC. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception 2008;77:22-29.
29. Bachmann G, Korner P. Bleeding patterns associated with non-oral hormonal contraceptives: a review of the literature. Contraception 2009;79:247-258.
30. Mansour D. The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception. Contra-ception 2012;85:224-234.
31. Ceci O, Bettocchi S, Pellegrino A, Impedovo L, Di Venere R, Pansini N. Comparison of hysteroscopic and hysterectomy findings for assessing the diagnostic accuracy of office hysteroscopy. Fertil Steril 2002;78:628-631.
32. Gallos ID, Ofinran O, Shehmar M, Coomarasamy A, Gupta JK. Current management of endometrial hyperplasia-a survey of United Kingdom consultant gynaecologists. Eur J Obstet Gynecol Reprod Biol 2011;158:305-307.
33. American Association of Gynecologic Laparoscopists. AAGL practice report: practice guidelines for the diagnosis and management of endometrial polyps. J Minim Invasive Gynecol 2012;19:3-10.
34. Haynes PJ, Hodgson H, Anderson AB, Turnbull AC. Measurement of menstrual blood loss in patients com-plaining of menorrhagia. Br J Obstet Gynaecol 1977;84: 763-768.
35. Demirkiran F, Yavuz E, Erenel H, Bese T, Arvas M, Sanioglu C. Which is the best technique for endometrial sampling? Aspiration (pipelle) versus dilatation and curettage (D&C). Arch Gynecol Obstet 2012;286:1277-1282.
36. Lee TS, Seong SJ, Kim JW, Ryu HS, Song ES, Nam BH. Management of endometrial hyperplasia with a levonor-gestrel-releasing intrauterine system: single arm, pro-spective multicenter study: Korean Gynecologic Oncology Group Study (KGOG2006). Jpn J Clin Oncol 2011;41:817-819.